Short- and long-term effects of 186Re-1,1-hydroxyethylidene diphosphonate in the treatment of painful bone metastases

Journal of Nuclear Medicine

Volumn 41, Issue 4, 2000, Pages 647-654

  Sciuto, Rosa ^a,b   Tofani, Anna ^a   Festa, Anna ^a   Giannarelli, Diana ^a   Pasqualoni, Rosella ^a   Maini, Carlo L ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b NONE   (Italy)

Author keywords

186Re hydroxyethylidene diphosphonate; Bone metastases; Radionuclide therapy

Indexed keywords

1,1 HYDROXYETHYLIDENE DIPHOSPHONATE; ALKALINE PHOSPHATASE; BISPHOSPHONIC ACID DERIVATIVE; OSTEOPAL; RHENIUM 186; TUMOR MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BLOOD TOXICITY; BONE METASTASIS; BONE PAIN; DRUG MIXTURE; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

AGED; BONE NEOPLASMS; BREAST NEOPLASMS; ETIDRONIC ACID; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; ORGANOMETALLIC COMPOUNDS; PAIN, INTRACTABLE; PALLIATIVE CARE; PROSTATIC NEOPLASMS; RADIOISOTOPES; TIME FACTORS;

EID: 0034079651     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Pecher C. Biological investigation with radioactive calcium and strontium: preliminary report on the use of radioactive strontium in the treatment of metastatic bone cancer. Univ Calif Pub Pharmacol. 1942;2:117-149.
2. Silberstein EB, Williams C. Strontium-89 therapy for the pain of osseous metastases. J Nucl Med. 1985;26:345-348.
3. Robinson RG, Prestom DF, Schiefelbein M, et al. Strontium-89 therapy for the palliation of pain due to osseous metastases. JAMA. 1995;274:420-424.
4. Porter AT, Mc Ewan AJB, Power JE, et al. Results of a randomized phase III trial to evaluate the efficacy of strontium-89 adjuvant to local field external beam irradiation in the management of endocrine resistant metastatic prostate cancer. Int J Radiat Oncol Biol Phys. 1993;25:805-813.
5. 186Re-HEDP as bone therapeutic radiopharmaceuticals. Nucl Med Biol. 1987;14:223-232.
6. Maxon HR, Schroder LE, Hertzberg VS, et al. Rhenium-186(Sn) HEDP for treatment of painful osseous metastases: results of a double blind comparison with placebo. J Nucl Med. 1991;32:1877-1881.
7. de Klerk JMH, Zonnenberg BA, van het Schip AD, et al. Dose escalation study of rhenium-186-hydroxyethylidene diphosphonate in patient with metastatic prostate cancer. Eur J Nucl Med. 1994;21:1114-1120.
8. de Klerk JMH, van Dieren EB, van het Schip AD, et al. Bone marrow adsorbed dose of rhenium-186-HEDP and the relationship with decreased platelet counts. J Nucl Med. 1996;37:38-41.
9. Maxon HR, Deutsch EA, Thomas SE, et al. Re-186(Sn)HEDP for treatment of multiple metastatic foci in bone: human distribution and dosimetric studies. Radiology. 1988;166:501-507.
10. de Klerk JMH, van Dijk A, van het Schip AD, et al. Pharmacokinetics of rhenium-186 after administration of rhenium-186-HEDP to patients with bone metastases. J Nucl Med. 1992;33:646-651.
11. Maxon HR, Schroder LE, Thomas SR, et al. Re-186(Sn)HEDP for treatment of painful osseous metastases: initial clinical experience in 20 patients with hormone-resistant prostate cancer. Radiology. 1990;176:155-159.
12. Maxon HR, Thomas SR, Hertzberg VS, et al. Rhenium-186 hydroxyethylidene diphosphonate for treatment of painful osseous metastases. Semin Nucl Med. 1992;22:33-40.
13. Quirijnen MSP, Han SH, Zonnenberg BA, et al. Efficacy of rhenium-186-etidronate in prostate cancer patients with metastatic bone pain. J Nucl Med. 1996;37:1511-1515.
14. Abram SE, Haddox JD, Kettler RE. The Pain: Clinic Manual. Philadelphia, PA: JB Lippincott; 1990.
15. Foley KM. Management of cancer pain. In: De Vita VT, Hellman S, Rosemberg SA, eds. Cancer: Principles and Practice of Oncology, 4th ed. Philadelphia, PA: JB Lippincott; 1993:2421-2448.
16. Soloway MS, Hardeman SW, Hickey D, et al. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988;61:195-202.
17. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva, Switzerland: World Health Organization; 1979. Offset publication 48.
18. Motulsky H. Intuitive Biostatistics. New York, NY: Oxford University; 1995.
19. Mc Ewan AJB. Unsealed source therapy of painful bone metastases: an update. Semin Nucl Med. 1997;2:165-182.
20. Kaplan E, Fels IG, Kotlowski BR. Therapy of carcinoma of the prostate metastatic to bone with P-32 condensed phosphate. J Nucl Med. 1960;1:1-13.
21. Farhanghi M, Holmes RA, Volker WA, et al. Samarium 153-EDTMP: pharmacokinetic, toxicity and pain response using an escalating dose schedule in treatment of metastatic bone cancer. J Nucl Med. 1992;33:1451-1458.
22. Silberstein EB, Elgazzar AH, Kapilivsky A. Phosphorus-32 radiopharmaceuticals for the treatment of painful osseous metastases. Semin Nucl Med. 1992;22:17-27.
23. Aziz H, Choi K, Sohn C, Yaes R, Rotman M. Comparison of P32 and SHB1 for bony metastases. Am J Clin Oncol. 1986;9:264-268.
24. Turner JH, Claringbold PG. A phase II study of treatment of painful multifocal skeletal metastases with single and repeated dose samarium-153 ethylenediamine-tetramethylene phosphonate. Eur J Cancer. 1991;27:1084-1086.
25. Sandeman TF, Budd RS, Martin JJ. Samarium-153-labeled EDTMP for bone metastases from cancer of the prostate. Clin Oncol. 1992;4:160-164.
26. Blake GM, Zivanovic MA, McEwan AJ, Ackery DM. Strontium kinetics in disseminated carcinoma of the prostate. Eur J Nucl Med. 1986;12:447-454.
27. Lin WY, Lin CP, Yeh SJ, et al. Rhenium-186 hydroxyethylidene diphosphonate: a new generator-produced radiotherapeutic drug of potential value for the treatment of bone metastases. Eur J Nucl Med. 1997;24:590-595.
28. de Klerk JMH, van het Schip AD, Zonnemberg BA, van Dijk A, Blijam GH, van Rijk PP. Phase I study of Re-186-HEDP in patients with bone metastases originating from breast cancer. J Nucl Med. 1996;37:244-249.
29. Zonnenberg BA, de Klerk JMK, van Rijk PP, et al. Re-186-HEDP for treatment of painful bone metastases in patients with metastatic prostate or breast cancer, preliminary results [abstract]. J Nucl Med. 1991;32(suppl):1082P.
30. Geldof AA, Van den Tillar PLM, Newling DWW, Teule GJJ. Radionuclide therapy for prostate cancer lumbar metastasis prolongs symptom-free survival in a rat model. Urology. 1997;49:795-801.